PCPo-Yuan Chen

Po-Yuan Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Po-Yuan Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Smoking-Thrombectomy Paradox: A Prospective Single-Center Study on the Impact of Smoking Status on Reperfusion Rates

    by Tzu-Ning Chen, Jyun-Yuan Huang, Te-Yuan Chen, Yu-Ying Wu, Po-Yuan Chen, Jui-Sheng Chen, Cheng-Loong Liang, Kang Lu, Hao-Kuang Wang

    Background: Smoking is a well-established risk factor for acute ischemic stroke, but its influence on endovascular thrombectomy outcomes remains unclear. While previous studies suggested a “smoking paradox” in thrombolysis, evidence regarding EVT is limited. Methods: We conducted a prospective, single-center observational study of 169 patients with acute ischemic stroke who underwent EVT between January 2019 and March 2023, using data from a tertiary hospital thrombectomy database in Kaohsiung, Taiwan. Patients were categorized as smokers (n=52) or non-smokers (n=117). Baseline characteristics were adjusted using inverse probability of treatment weighting. The primary endpoint was complete reperfusion. Secondary outcomes included NIHSS scores at admission and 24 hours post-procedure, modified Rankin Scale at discharge, and complications. Results: Smokers were younger and more often male, with lower rates of atrial fibrillation. After IPTW adjustment, smokers had significantly lower rates of complete reperfusion compared to non-smokers (30% vs. 53%; OR 0.39; 95% CI 0.19–0.79; p=0.01). They also presented with higher NIHSS scores at admission and 24 hours post-thrombectomy (p<0.05), and an increased risk of stroke-associated pneumonia (OR 2.98; p=0.003). No significant difference in discharge mRS was observed. Conclusions: Smoking is associated with reduced reperfusion success, worse neurological status, and higher pneumonia risk after EVT, but not with short-term functional outcome. These findings contradict the notion of a smoking–reperfusion paradox in EVT-treated AIS patients.

  • Phosphaturic Mesenchymal Tumors in C-Spine

    by Po-Yuan Chen, Kang Lu, Lee-Ren Yeh, Jen-Wei Tsai, Chao-Tien Hsu

  • Open Access

    Nationwide Big Data Analysis of Statin Use and Intracerebral Hemorrhage Risk in Acute Ischemic Stroke Patients in Taiwan

    by William Winardi, Sin-Hua Moi, Thomas Winardi, Yu-Wen Cheng, Po-Yuan Chen, Cheng-Kai Lin

    Background and Objectives: Although statins are recommended for secondary prevention of acute ischemic stroke, some population-based studies and clinical evidence suggest that they might be used with an increased risk of intracranial hemorrhage. In this nested case–control study, we used Taiwan’s nationwide universal health insurance database to investigate the possible association between statin therapy prescribed to acute ischemic stroke patients and their risk of subsequent intracerebral hemorrhage and all-cause mortality in Taiwan. Materials and Methods: All data were retrospectively obtained from Taiwan’s National Health Insurance Research Database. Acute ischemic stroke patients were divided into a cohort receiving statin pharmacotherapy and a control cohort not receiving statin pharmacotherapy. A 1:1 matching for age, gender, and index day, and propensity score matching was conducted, producing 39,366 cases and 39,366 controls. The primary outcomes were long-term subsequent intracerebral hemorrhage and all-cause mortality. The competing risk between subsequent intracerebral hemorrhage and all-cause mortality was estimated using the Fine and Gray regression hazards model. Results: Patients receiving statin pharmacotherapy after an acute ischemic stroke had a significantly lower risk of subsequent intracerebral hemorrhage (p < 0.0001) and lower all-cause mortality rates (p < 0.0001). Low, moderate, and high dosages of statin were associated with significantly decreased risks for subsequent intracerebral hemorrhage (adjusted sHRs 0.82, 0.74, 0.53) and all-cause mortality (adjusted sHRs 0.75, 0.74, 0.74), respectively. Conclusions: Statin pharmacotherapy was found to safely and effectively reduce the risk of subsequent intracerebral hemorrhage and all-cause mortality in acute ischemic stroke patients in Taiwan.